Grant from the company NanoString, who supplies reagents to perform Tumor Signaling (TS360) gene expression profiling on 12 oral head and neck squamous cell carcinoma samples to determine whether localization of GARP on tumor cells relates to alterations in gene expression in the tumor as well as immune cell infiltration within the tumor microenvironment